Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report

BACKGROUND: Regorafenib is an oral multikinase inhibitor that has been demonstrated as clinically effective in patients with metastatic colorectal cancer in phase III studies. Although disease control was achieved in 40% of the pretreated patients with metastatic colorectal cancer in the pivotal stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, Kenji, Manaka, Dai, Kudo, Ryo, Kanai, Shunpei, Mitsuoka, Eisei, Kanto, Satoshi, Hamasu, Shinya, Konishi, Sayuri, Nishitai, Ryuta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561601/
https://www.ncbi.nlm.nih.gov/pubmed/28818109
http://dx.doi.org/10.1186/s13256-017-1366-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561601/
https://www.ncbi.nlm.nih.gov/pubmed/28818109
http://dx.doi.org/10.1186/s13256-017-1366-4

Ejemplares similares